3P and their collaborators have developed and tested a novel uterine cervical implant device, PolyC™, for drug delivery that continuously releases drugs locally for the treatment of high-risk patients with advanced cervical dysplasia, cervical cancer, and other cervical, vaginal, and vulva diseases. The PolyC™ implant, prepared from a cost-effective and biodegradable polymer, polycaprolactone, promises a major advance in the treatment of cervical pathologies in women.

 

Treatment using this new patient-friendly, minimally invasive device would be economical, would provide the first non-surgical option for the management of uterine cervical abnormalities, and may obviate the need for the loop electrosurgical excision procedure (LEEP).

​

Also developed are cylindrical implants of plant bioactives for continuous subcutaneous delivery for months for chemopreventive and therapeutic effects in animal models.

​

These new devices can provide an extended and continuous drug release locally and systemically for many months. This local drug delivery device, invented by Dr. Gupta, and his collaborators at the University of Louisville, has exhibited no toxicity, and successful testing in a large animal model.